The global pharmaceutical contract sales organizations market size is estimated to reach USD 18.14 billion by 2030, expanding at a CAGR of 8.83% from 2025 to 2030, according to a new report by Grand View Research, Inc. High adoption of new technologies for contract sales by pharmaceutical contract sales organizations (CSO), an increase in the interest among end-users to increase the sales of biopharmaceutical and small molecule drugs, and the surge in demand for reducing the cost associated with in-house sales are some of the key factors supporting the growth of the industry. Over the years, the number of new drug launches has increased.
For instance, according to the IQVIA report on R&D trends, 84 new active substances were launched globally in 2021, which was double as compared to the last five years. The increase in drug launches globally is expected to improve the demand for contract sales services, which is likely to support industry growth. Prescription drug sales are witnessing a steady rise. For instance, according to Evaluate Pharma, worldwide total prescription drug sales accounted for USD 1,066 billion in 2021 and will reach USD 1,612 billion by 2028. The growing demand for sales among pharmaceutical companies is expected to improve the demand for CSO services for pharmaceuticals in the post-pandemic period.
Request a free sample copy or view the report summary: Pharmaceutical Contract Sales Organizations Market Report
Based on service, the personal promotion segment dominated the industry in 2024. A rise in the R&D activities of pharmaceutical companies is expected to increase the number of new drug launches, and approvals are expected to support the segment growth
The pharmaceutical companies end-use segment held the largest revenue share in 2024 due to the high competition among pharmaceutical companies in product sales, promoting the demand for an efficient team to support their sales activities
North America held the largest revenue share in 2024. A significant number of drugs were launched in the region in the previous years, especially in the U.S., which is one of the key factors supporting the region’s growth
Moreover, the region’s public organization is steadily focused on supporting R&D activities by providing funding. This has further supported the region’s growth
Grand View Research has segmented the global pharmaceutical contract sales organizations market based on service, therapeutic areas, end use, and region:
Pharmaceutical Contract Sales Organizations Services Outlook (Revenue, USD Million, 2018 - 2030)
Personal Promotion
Promotional sales team
Key account management
Vacancy management
Non-personal promotion
Medical affairs solutions
Remote medical science liaisons
Nurse educators
Others
Pharmaceutical Contract Sales Organizations Therapeutic Areas Outlook (Revenue, USD Million, 2018 - 2030)
Oncology
Cardiovascular
Neurology
Infectious Diseases
Metabolic Disorders
Orthopedic Diseases
Others
Pharmaceutical Contract Sales Organizations End Use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical Companies
Biopharmaceutical Companies
Pharmaceutical Contract Sales Organizations Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Pharmaceutical Contract Sales Organizations Market
CMIC Holdings Co., Ltd.
Axxelus
EPS Corp.
QFR Solutions
MaBico
Mednext Pharma Pvt. Ltd.
Peak Pharma Solutions Inc.
IQVIA, Inc.
Promoveo Health
Syneous Health
"The quality of research they have done for us has been excellent..."